|
1
|
Torre LA, Trabert B, DeSantis CE, Miller
KD, Samimi G, Runowicz CD, Gaudet MM, Jemal A and Siegel RL:
Ovarian cancer statistics, 2018. CA Cancer J Clin. 68:284–296.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Bray F, Ferlay J, Soerjomataram I, Siegel
RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN
estimates of incidence and mortality worldwide for 36 cancers in
185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Burges A and Schmalfeldt B: Ovarian
cancer: Diagnosis and treatment. Dtsch Arztebl Int. 108:635–641.
2011.PubMed/NCBI
|
|
4
|
Fotopoulou C: Limitations to the use of
carboplatin-based therapy in advanced ovarian cancer. EJC Suppl.
12:13–16. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Agarwal R and Kaye SB: Ovarian cancer:
Strategies for overcoming resistance to chemotherapy. Nat Rev
Cancer. 3:502–516. 2003. View
Article : Google Scholar : PubMed/NCBI
|
|
6
|
Damia G and Broggini M: Platinum
resistance in ovarian cancer: Role of DNA repair. Cancers (Basel).
11:1192019. View Article : Google Scholar
|
|
7
|
John B, Naczki C, Patel C, Ghoneum A,
Qasem S, Salih Z and Said N: Regulation of the bi-directional
cross-talk between ovarian cancer cells and adipocytes by SPARC.
Oncogene. 38:4366–4383. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Tang J, Pulliam N, Ozes A, Buechlein A,
Ding N, Keer H, Rusch D, O'Hagan H, Stack MS and Nephew KP:
Epigenetic targeting of adipocytes inhibits High-Grade serous
ovarian cancer cell migration and invasion. Mol Cancer Res.
16:1226–1240. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Nieman KM, Kenny HA, Penicka CV, Ladanyi
A, Buell-Gutbrod R, Zillhardt MR, Romero IL, Carey MS, Mills GB,
Hotamisligil GS, et al: Adipocytes promote ovarian cancer
metastasis and provide energy for rapid tumor growth. Nat Med.
17:1498–1503. 2011. View
Article : Google Scholar : PubMed/NCBI
|
|
10
|
Miranda F, Mannion D, Liu S, Zheng Y,
Mangala LS, Redondo C, Herrero-Gonzalez S, Xu R, Taylor C, Chedom
DF, et al: Salt-inducible kinase 2 couples ovarian cancer cell
metabolism with survival at the Adipocyte-Rich metastatic niche.
Cancer Cell. 30:273–289. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Ladanyi A, Mukherjee A, Kenny HA, Johnson
A, Mitra AK, Sundaresan S, Nieman KM, Pascual G, Benitah SA, Montag
A, et al: Adipocyte-induced CD36 expression drives ovarian cancer
progression and metastasis. Oncogene. 37:2285–2301. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Nowicka A, Marini FC, Solley TN, Elizondo
PB, Zhang Y, Sharp HJ, Broaddus R, Kolonin M, Mok SC, Thompson MS,
et al: Human omental-derived adipose stem cells increase ovarian
cancer proliferation, migration, and chemoresistance. PLoS One.
8:e818592013. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Cardenas C, Montagna MK, Pitruzzello M,
Lima E, Mor G and Alvero AB: Adipocyte microenvironment promotes
Bclxl expression and confers chemoresistance in ovarian
cancer cells. Apoptosis. 22:558–569. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Schmittgen TD and Livak KJ: Analyzing
real-time PCR data by the comparative C(T) method. Nat Protoc.
3:1101–1108. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Huang RL, Teo Z, Chong HC, Zhu P, Tan MJ,
Tan CK, Lam CR, Sng MK, Leong DT, Tan SM, et al: ANGPTL4 modulates
vascular junction integrity by integrin signaling and disruption of
intercellular VE-cadherin and claudin-5 clusters. Blood.
118:3990–4002. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Wang WW, Wang YB, Wang DQ, Lin Z and Sun
RJ: Integrin beta-8 (ITGB8) silencing reverses gefitinib resistance
of human hepatic cancer HepG2/G cell line. Int J Clin Exp Me.
8:3063–3071. 2015.
|
|
17
|
Santos AR, Corredor RG, Obeso BA,
Trakhtenberg EF, Wang Y, Ponmattam J, Dvoriantchikova G, Ivanov D,
Shestopalov VI, Goldberg JL, et al: β1 integrin-focal adhesion
kinase (FAK) signaling modulates retinal ganglion cell (RGC)
survival. PLoS One. 7:e483322012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Lim MMK, Wee JWK, Soong JC, Chua D, Tan
WR, Lizwan M, Li Y, Teo Z, Goh WWB, Zhu P and Tan NS: Targeting
metabolic flexibility via angiopoietin-like 4 protein sensitizes
metastatic cancer cells to chemotherapy drugs. Mol Cancer.
17:1522018. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Yoshida H, Teramae M, Yamauchi M, Fukuda
T, Yasui T, Sumi T, Honda K and Ishiko O: Association of copper
transporter expression with platinum resistance in epithelial
ovarian cancer. Anticancer Res. 33:1409–1414. 2013.PubMed/NCBI
|
|
20
|
Surowiak P, Materna V, Maciejczyk A,
Pudełko M, Markwitz E, Spaczyński M, Dietel M, Zabel M and Lage H:
Nuclear metallothionein expression correlates with cisplatin
resistance of ovarian cancer cells and poor clinical outcome.
Virchows Arch. 450:279–285. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Liu J, Zhang L, Mao P, Jiang G, Liu L,
Wang J, Yang W, Owusu L and Li W: Functional characterization of a
novel transcript of ERCC1 in chemotherapy resistance of ovarian
cancer. Oncotarget. 8:85759–85771. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Ang JE, Gourley C, Powell CB, High H,
Shapira-Frommer R, Castonguay V, De Greve J, Atkinson T, Yap TA,
Sandhu S, et al: Efficacy of chemotherapy in BRCA1/2 mutation
carrier ovarian cancer in the setting of PARP inhibitor resistance:
A multi-institutional study. Clin Cancer Res. 19:5485–5493. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Helleman J, van Staveren IL, Dinjens WN,
van Kuijk PF, Ritstier K, Ewing PC, van der Burg ME, Stoter G and
Berns EM: Mismatch repair and treatment resistance in ovarian
cancer. BMC Cancer. 6:2012006. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Haslehurst AM, Koti M, Dharsee M, Nuin P,
Evans K, Geraci J, Childs T, Chen J, Li J, Weberpals J, et al: EMT
transcription factors snail and slug directly contribute to
cisplatin resistance in ovarian cancer. BMC Cancer. 12:912012.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
You Y, Bi FF, Jiang Y, Xu YT, An YY, Li D
and Yang Q: BRCA1 affects the resistance and stemness of
SKOV3-derived ovarian cancer stem cells by regulating autophagy.
Cancer Med. 8:656–668. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Borley J and Brown R: Epigenetic
mechanisms and therapeutic targets of chemotherapy resistance in
epithelial ovarian cancer. Ann Med. 47:359–369. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Lee JM, Hays JL, Annunziata CM, Noonan AM,
Minasian L, Zujewski JA, Yu M, Gordon N, Ji J, Sissung TM, et al:
Phase I/Ib study of olaparib and carboplatin in BRCA1 or BRCA2
mutation-associated breast or ovarian cancer with biomarker
analyses. J Natl Cancer Inst. 106:dju0892014. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Musa F, Alard A, David-West G, Curtin JP,
Blank SV and Schneider RJ: Dual mTORC1/2 inhibition as a novel
strategy for the resensitization and treatment of
platinum-resistant ovarian cancer. Mol Cancer Ther. 15:1557–1567.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Lei X, Shi F, Basu D, Huq A, Routhier S,
Day R and Jin W: Proteolytic processing of angiopoietin-like
protein 4 by proprotein convertases modulates its inhibitory
effects on lipoprotein lipase activity. J Biol Chem.
286:15747–15756. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Zhu P, Goh YY, Chin HF, Kersten S and Tan
NS: Angiopoietin-like 4: A decade of research. Biosci Rep.
32:211–219. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Tan MJ, Teo Z, Sng MK, Zhu P and Tan NS:
Emerging roles of angiopoietin-like 4 in human cancer. Mol Cancer
Res. 10:677–688. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Kobayashi M, Sawada K and Kimura T:
Potential of integrin inhibitors for treating ovarian cancer: A
literature review. Cancers (Basel). 9:832017. View Article : Google Scholar
|
|
33
|
Bose CK and Mukhopadhyay A: Claudin and
ovarian cancer. J Turk Ger Gynecol Assoc. 11:48–54. 2010.PubMed/NCBI
|
